H.C. Wainwright raised the firm’s price target on Corcept Therapeutics to $34 from $32 and keeps a Buy rating on the shares post the Q3 report. The analyst says Korlym growth “is far from reaching a plateau.” The firm sees multiple catalysts for Corcept ‘s Cushing’s syndrome franchise in 2024.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CORT:
- Corcept increases FY23 revenue view $470M-$480M from from $455M – $470M
- Corcept Therapeutics reports Q3 EPS 28c, consensus 22c
- Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics appoints Monica Tellado as president, emerging markets
- Corcept Appoints Monica Tellado as President, Emerging Markets